Skip to main content
. 2022 Feb 15;12(2):183. doi: 10.3390/metabo12020183

Table 3.

Summary of renal outcomes in RWS with GLP-1RA vs. other GLD (including SGLT-2i).

Boye et al. Boye et al. Lugner et al. Pasternak et al.
Main Baseline Features N 5932 2366 21,781 77,462
GLP-1RA - Dulaglutide 75.1% Liraglutide
16.3% Dulaglutide
6.4% Exenatide QW
92.5% Liraglutide
6.2% Exenatide
0.7% Lixisenatide
0.6% Dulaglutide
Comparator Other GLD Insulin Glargine SGLT-2i
(56.6% Empagliflozin
43.2% Dapagliflozin
0.2% Canagliflozin)
DPP-4i
Follow-up (yrs) 1 1 1.7–1.1 3.0
Mean age (yrs) 59.2 59.7 60.5 59.3
Female (%) 52.0 51.1 37.5 40.7
Mean diabetes duration (yrs) - - 7.5 -
Mean HbA1c (%) 8.4 8.3 8.3 -
Mean eGFR (mL/min/1.73 m2) 82.1 83.7 91.6 -
eGFR <60 mL/min/1.73 m2 (%) 19.4 18.2 - 4.6
Mean albuminuria (mg/L) - - - -
Microalbuminuria (%) - - 20.6 -
Macroalbuminuria (%) - - 4.3 -
Renal Outcomes Change in albuminuria
(mean (95% CI))
- - - -
New onset MA
(HR (95% CI))
- - 0.89 (0.77–1.04) -
Change in eGFR
(mL/min/1.73 m2)
−0.80 vs. −1.03
p = 0.0005
−0.4 vs. −0.9
p = 0.0024
- -
≥30% eGFR reduction 2.19% vs. 3.14%
p < 0.0001
3.3% vs 4.1%;
p < 0.0001
0.92 (0.68–1.25) § -
≥40% eGFR reduction
(HR (95% CI)) #
- - 0.94 (0.62–1.43) -
Composite renal
Outcome *
(HR (95% CI)) #
- - 0.98 (0.92–1.05) 0.76 (0.68–0.85)/0.60 (0.49–0.74)
Renal replacement
therapy (HR (95% CI)) #
- - - 0.73 (0.62–0.87)/0.42 (0.29–0.62)
Hospitalization for renal events (HR (95% CI)) # - - - 0.73 (0.65–0.83)/0.63 (0.50–0.78)
Renal death
(HR (95% CI)) #
- - - 0.72 (0.48–1.10)/0.66 (0.24–1.49)

GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT-2i, sodium-glucose cotransporter-2; GLD, glucose lowering drugs; DPP-4i, dipeptidyl peptidase-4 inhibitors; MA, macroalbuminuria. Statistically significant results are in bold. § HR (95% CI). # Results are presented as intention-to-treat/as-treated analyses. * Lugner et al.: any of micro- or macroalbuminuria, eGFR 50% reduction or lower than 60, dialysis, renal transplantation, renal failure, renal death; Pasternak et al.: renal replacement therapy, hospitalization for renal causes and death for renal causes.